PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC

Oliver Sartor, MD, of Mayo Clinic in Rochester, Minnesota, discusses the results of the phase 3 PSMAfore study, which examined [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in taxane-naïve patients with metastatic castration-resistant prostate cancer. Dr. Sartor gives a summary of the trial and its key results, and shares his thoughts on the key considerations for clinicians when deciding to incorporate this therapy into their treatment regimens.

Watch Dr. Sartor explain the methodology, nuances, and implications of the PSMAfore trial here: PSMAfore: Methodology, Nuances, and Implications